Monday, September 26, 2022
HomePress ReleasesDuchenne muscular dystrophy treatment market 2030 | A report on emerging markets...

Duchenne muscular dystrophy treatment market 2030 | A report on emerging markets through 2030 is based on historical data and trends from emerging markets, company profiles, and growth factors in emerging markets.


Torrance, California, USA -As per MarkWide Research’s latest study, Duchenne muscular dystrophy treatment market indicates that the CAGR between 2022 and 2030 will be 10.62%, which is in line with the projected growth rate.

Duchenne muscular dystrophy (DMD), also known as Duchenne muscular atrophy (DMA), is a rare genetic disease characterized by progressive muscle weakness and degeneration caused by alterations to a protein called dystrophin. A recessive disease associated with X chromosomes affecting predominantly males, the condition also affects female carriers. 

Despite the fact that females are generally not affected, some may display a milder form of the disease (“manifesting carriers”) such as mild muscular weakness, cramps, and cardiac changes. As a result of dystrophin not being present in muscle cells, they are fragile, easy to damage, and most people who are affected by DMD require a wheelchair by the time they reach adulthood. DMD patients between the ages of 19 and 25 are subject to serious life-threatening conditions such as cardiomyopathy and respiratory difficulties which eventually lead to mortality if untreated.

BRIEF OVERVIEW

  • Among the key factors driving the global duchenne muscular dystrophy market are the introduction of novel drugs, disease-modifying therapies, the strong support of various companies in the development of new drugs, and the support of patient advocacy groups in the approval process of new drugs and therapies. 
  • A major breakthrough in the treatment of duchenne muscular dystrophy is likely to come as a result of the development of mutation-specific therapies.
  • As part of the development of new drugs and therapies, drug developers are focusing on targeting newborns, young infants and also the last-stage patients with DMD who are suffering from the disease. 
  • As a result of rapid development in duchenne muscular dystrophy therapeutics in the past few years, there has been significant progress made in this field. 
  • The high cost of therapies and drugs, however, continues to prevent a large number of patients from being able to make use of these treatments and drugs due to their high price tags and lack of awareness.

Download PDF Sample of our latest report: https://markwideresearch.com/download-sample?productid=5015&submitTitle=Download+Sample 

COVID-19 Impact analysis

The COVID-19 virus is an infectious disease that emerged in China in late December in the Hubei province and the city of Wuhan in the Hubei province. SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) is a highly contagious and highly contagious disease that is caused by a virus and is transmitted from person to person by contact with the virus. There have been outbreaks of the disease in almost 213 countries all over the world since December 2019, which led the World Health Organization to declare it a pandemic on March 11, 2020.

  • There is an ongoing collaboration between pharmaceutical companies and biotech companies, as well as governments around the globe, to address the COVID-19 outbreak, ranging from the development of vaccines to planning for challenges in the medicine supply chain. 
  • In the R&D pipeline, there are currently around 115 vaccine candidates and 155 molecules being investigated. NCBI reported that one out of 116 patients with duchenne muscular dystrophy was found to have been infected with Covid-19, out of 116. 
  • There has been a dramatic increase in the demand for common drugs such as corticosteroids that are used to manage the symptoms of duchenne muscular dystrophy in patients with COVID-19. 
  • Since there is a shortage of COVID-19 management drugs in many developed countries, there has been a large opportunity for manufacturers of these drugs to profit from such high demand for these drugs. 
  • Due to the increased demand for corticosteroids drugs for COVID-19, it is expected that the pharmaceutical and biotechnology industries will experience a significant growth in the future. As a consequence, the demand for duchenne muscular dystrophy products is expected to be significantly affected by this change.

Factors that have the greatest impact on the industry

  • There are several factors influencing the growth of the duchenne muscular dystrophy market. These factors include increased awareness campaigns about the disorder, the development of mutation-specific therapies for it, the increase in prevalence of the duchenne muscular dystrophy market, an increase in the number of products that are being developed, an increase in the number of therapies like Exondys51, Translarna, the introduction of exon skipping technologies, and the introduction of corticosteroid-based anti-inflammatory treatment.
  • A number of factors are also contributing to the growth of the duchenne muscular dystrophy market, including an increase in healthcare expenditures, an increase in skilled professionals, collaborations and partnerships between key players, an increase in R&D activities aimed at improving drug quality, and the introduction of new drugs, such as Ataluren, to treat children aged five and older with duchenne muscular dystrophy.
  • The market growth, however, is expected to be hindered by the high cost of treatment.
  • Contrary to what many think, favorable reimbursement policies and the support from the government for the approval of regulatory measures provide new avenues of growth for the industry.

Aims and objectives

  • There is a wide range of information regarding DMD including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and guidelines for treatment.
  • During the forecast period, the following information will be provided: the topline revenue of the DMD market, the annual cost of therapy, and major pipeline products.
  • Among the topics that will be discussed are current treatments of DMD and pipeline treatments, unmet needs and opportunities, as well as the drivers and barriers affecting the sale of DMD therapeutics in the US and Japan.
  • Data analysis of pipeline drugs: Comprehensive data across different stages of development, emerging novel trends under development, as well as a detailed analysis of late-stage pipeline drugs are included in this report.
  • The current and future state of competition in the market for DMD in the US and Japanese markets has been analyzed. This paper provides a comprehensive analysis of the key drivers, restraints, and challenges driving the industry.

Design this research as per your need: https://markwideresearch.com/request-for-customization/?productid=5015&submitTitle=Request+for+Customization 

Duchenne muscular dystrophy treatment market Major Players Covered:

  • ITALFARMACO S.p.A.,
  • FibroGen, Inc.,
  • Summit Therapeutics plc,
  • PTC Therapeutics,
  • Santhera Pharmaceuticals,
  • Sarepta Therapeutics, Inc.
  • Others

Duchenne muscular dystrophy treatment market Segmentation Analysis:

Product Type
  • NSAIDs
  • Corticosteroids
  • Other Products
Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Therapy
  • Mutation Suppression
  • Exon Skipping Approach
  • Others Therapies

Duchenne muscular dystrophy treatment market Geographical Segmentation Includes:

  • North America
  • Europe
  • Asia Pacific
  • South America
  • The Middle East & Africa

Get this Full Research at discounted rate: https://markwideresearch.com/checkout/?add-to-cart=5015&quantity=1 

About MarkWide Research:

MarkWide Research has established itself as an innovative and neoteric Market research consulting firm unmatched in terms of adaptability and integrated strategies. We’re determined to find the most profitable market opportunities and provide efficient data for your company to succeed in the market. MarkWide endeavours to provide suitable solutions to complex business issues and facilitates an uncomplicated decision-making process. MarkWide is an aftermath of pure wisdom and experience that was developed and established in 2016

MarkWide Research has more than 500 analysts in a variety of fields. We’ve served over 40% of Fortune 500 companies worldwide and have an extensive network of five thousand clients worldwide. MarkWide Research is adept at creating happy clients who trust our services and trust our work with confidence. We are satisfied with our dazzling client satisfaction rate.

Contact:
MarkWide Research

444 Alaska Avenue Suite 

#BAA205 Torrance, CA 90503 USA
US: +1 424-373-8777
Email: [email protected]

Website: markwideresearch.com



Source link

RELATED ARTICLES

Most Popular

Recent Comments